RxDoctor Payments DataLook up a doctor →

Anace Said, MD

Internal Medicine · Wallingford, CTNPI 1487696910

Payments from drug & device makers

$52,503in general payments, 2019–2025

Across 1,275 payments — averaging $41.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$16K
  • Indivior Inc.$10K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • AbbVie$4K
  • Johnson & Johnson$2K
  • Merz North America, Inc.$2K
  • plus $15K from 53 others

What the payments were for

  • Consulting fees$6,15012%
  • Speaking & faculty fees$17,17533%
  • Travel & lodging$4,3438%
  • Food & beverage$24,76947%
  • Education$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
MDD US Operations, LLC91$15,528
Indivior Inc.70$9,753
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC185$4,317
AbbVie(2 entities)133$4,317
Johnson & Johnson82$1,911
Merz North America, Inc.16$1,826
Biohaven Pharmaceuticals, Inc.5$1,384
Lilly USA, LLC56$1,177
Scilex Pharmaceuticals Inc.51$991
USWM, LLC61$882
AstraZeneca31$870
Takeda Pharmaceuticals U.S.A., Inc.38$818
Pfizer48$782
Gilead42$760
Orexo US, Inc.48$688
Viiv Healthcare Company38$618
Lundbeck LLC23$586
Axsome Therapeutics, Inc.23$549
Paratek Pharmaceuticals, Inc.37$492
Alkermes, Inc.20$422
Braeburn Inc.19$399
Boehringer Ingelheim22$371
Otsuka America Pharmaceutical, Inc.11$293
Dermira, Inc.8$292
EMD Serono, Inc.2$245
Amgen(2 entities)12$217
GSK10$188
Corium, LLC8$161
Novo Nordisk8$158
Astellas Pharma US Inc5$146
Exact Sciences7$141
Hikma Pharmaceuticals USA7$125
Sanofi4$115
Amarin Pharma, Inc.6$113
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$107
Teva Pharmaceuticals USA, Inc.5$86
Currax Pharmaceuticals LLC5$78
Biohaven Pharmaceutical Holding Company Ltd.4$67
Jazz Pharmaceuticals Inc.3$54
Shire North American Group Inc3$54
Abbott2$47
Zyla Life Sciences, Inc.2$38
Avanir Pharmaceuticals, Inc.2$37
Collegium Pharmaceutical, Inc.2$37
Inspire Medical Systems, Inc.1$25
Novartis1$22
Adlon Therapeutics L.p.1$22
Organon1$21
Neos Therapeutics, LP1$19
Intra-sana Laboratories1$19
Actelion Pharmaceuticals US, Inc.1$18
Merck1$17
Redhill Biopharma Inc.1$16
Watermark Medical, Inc.1$16
Echosens North America, Inc.1$15
Kyowa Kirin, Inc.1$14
Supernus Pharmaceuticals, Inc.1$14
Melinta Therapeutics, LLC1$14
Athena Bioscience, LLC1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,503 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$23,680
Medicare patients
24
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide21$24,046
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl45$8,113
Metformin Hcl ErMetformin Hcl19$482
Venlafaxine Hcl ErVenlafaxine Hcl12$196
Atorvastatin Calcium14$95
Lisinopril18$95
Rosuvastatin Calcium13$84
Tramadol Hcl16$80
Amlodipine Besylate13$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,177$24,04621 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$125$8,11345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →